Trials / Completed
CompletedNCT00802464
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 410 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes zoster vaccine GSK1437173A | 2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations) |
| BIOLOGICAL | Placebo | 2 vaccinations at Months 0 and 2 with placebo |
Timeline
- Start date
- 2009-01-12
- Primary completion
- 2010-07-02
- Completion
- 2010-07-02
- First posted
- 2008-12-05
- Last updated
- 2019-06-26
- Results posted
- 2017-12-12
Locations
12 sites across 3 countries: United States, Czechia, Spain
Source: ClinicalTrials.gov record NCT00802464. Inclusion in this directory is not an endorsement.